MedTrace Logo

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

NCT07159750 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2025-09-08

No results posted yet for this study

Summary

The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.

Conditions

  • Migraine
  • Episodic Migraine
  • Chronic Migraine, Headache

Interventions

DRUG

CGRP antibody or gepant

Patients will start anti-CGRP or its receptor antibody or gepants

Sponsors & Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Principal Investigators

  • Patricia Pozo-Rosich, MD, PhD · Vall d'Hebron University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-02
Primary Completion
2026-01-31
Completion
2026-01-31
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Chile
  • Colombia
  • Croatia
  • Germany
  • Italy
  • Malaysia
  • Norway
  • Poland
  • Portugal
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07159750 on ClinicalTrials.gov